Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study. - Nabholtz,J.; Pienkowski,T.; Mackey,J.; Pawlicki,M.; Guastalla,J.P.; Vogel,C.; Weaver,C.; Walley,M. (Proc ASCO, 2002)